CEOCFO.biz Features Herborium Group as Industry Innovator in Recent News Story.TEANECK, N.J. -- Herborium Group, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :HBRM), a developer and marketer of novel botanical therapeutics([R]), announced today that on April 12, 2007, an interview CEOCFO.biz conducted with Dr. Agnes Olszewski, Herborium's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , was released online by this powerful, bi-weekly Internet publication (http://ceocfointerviews.com/interviews/HBRM-Herborium.htm). CEOCFO.biz has over 100,000 individual and corporate readers each month representing business and investment communities worldwide, and features interviews with companies publicly traded on US and Canadian stock exchanges, and venture capitalists Venture Capitalist An investor who provides capital to either start-up ventures or support small companies who wish to expand but do not have access to public funding. Notes: Venture capitalists usually expect higher returns for the additional risks taken. . The focal point focal point n. See focus. of the story is the rapidly growing market for botanically based medicinal products medicinal product, n a substance administered to humans or animals through injection, application, oral ingestion, inhalation, and so forth, whose purpose is to ultimately restore health or eliminate disease in an individual. and Herborium's business strategy as a leading industry innovator. This new, potentially $500B market is supported by recent changes in the FDA's regulatory approach (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. 2004 Guidance For Industry Botanic Drugs Products), the erosion of consumer trust with ethical pharmaceuticals such as Vioxx and HRT HRT abbr. hormone replacement therapy Hormone replacement therapy (HRT) Also called estrogen replacement therapy, this controversial treatment is used to relieve the discomforts of menopause. due to recent safety problems, and the economics of botanical therapeutics, and botanical drugs which can be developed more quickly and economically than traditional pharmaceuticals. "Herborium is one of the few players in this emerging niche. With our unique botanical therapeutic product candidates, innovative business model and science and marketing partners in the US, Asia and Europe, we expect to more than just make a mark on this emerging sector - we expect to own part of it," said Dr. Olszewski. This release and oral statements made from time to time by the Company's representatives concerning the same subject matter may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by the Company with the SEC, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. |
|
||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion